Vaccination Plus Ontak in Patients With Metastatic Melanoma
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if an experimental melanoma vaccine can produce an
immune response in patients with metastatic melanoma, and if combining this vaccine with the
drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor
shrinkage.